Switching MS Medications: Tracking Immune Protein Changes
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study follows adults with relapsing multiple sclerosis who are switching from ocrelizumab to ofatumumab (two similar MS medications) to see how their immune system proteins (immunoglobulins) change during the switch. It may help doctors understand if this change improves your immune health while treating MS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have relapsing-form multiple sclerosis and have taken ocrelizumab for at least 18 months
- Your blood tests showed decreased immunoglobulin (immune proteins) on at least two separate tests about 6 months apart while on ocrelizumab
- You are switching or have already switched from ocrelizumab to ofatumumab (your doctor decided this separately from the study)
- You are not pregnant and do not plan to become pregnant during the study
- You have not received immunoglobulin infusions (supplemental immune proteins) in the past 18 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
This study tests whether switching from ocrelizumab to a similar drug, ublituximab, can help people with MS who experience 'wearing-off' symptoms before their next infusion. It may offer a new option to keep symptoms more stable between doses.
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This study looks at how ofatumumab (Kesimpta) affects the back of the eye (retina) and certain nerve proteins in the blood in people with relapsing multiple sclerosis. It may help doctors understand how well the medication is protecting the eyes and nerves.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.